Results 221 to 230 of about 1,819,629 (315)

Co-developing a vocational rehabilitation intervention for individuals with chronic low back pain across a regional spine centre and three municipalities in Denmark: a three-stage intervention development study guided by the Medical Research Council framework. [PDF]

BMJ Open
Frydenlund G, Mortensen OS, O'Neill S, Søndergaard J, Hansen A.   +4 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

A complex intervention to improve life experience during and after acute treatment for breast cancer: Preliminary results from intervention development for the Continuum PAROLE-Onco 360 program. [PDF]

Can J Public Health
Pomey MP, Nabi H, Coté MA, Iliescu Nelea M, Boubaker A, Vialaron C, Normandin L, Lesperance-Huot C.   +7 more
europepmc   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Developing the PATH-GP (Prevention and Testing for HIV in General Practice) intervention: a person-based approach intervention development study to increase HIV testing and PrEP access. [PDF]

Br J Gen Pract
Scott A, Family H, Horwood J, Saunders J, Sullivan A, Burgin J, Harryman L, Stockwell S, Copping J, Sheehan P, Macleod J, Dawson S, Dawson S, Kesten JM, Denford S.   +14 more
europepmc   +1 more source

The Development of the Intervention in Haiti [PDF]

The Hispanic American Historical Review, 1927
openaire   +1 more source

DEVELOPMENTS IN CLINICAL INTERVENTIONS [PDF]

The Gerontologist, 2016
openaire   +1 more source

Astrocyte heterogeneity in brain metastases

Molecular Oncology, EarlyView.
Astrocytes emerge as pivotal regulators of metastatic colonization, survival, immune remodeling, and therapy response associated with an increasing heterogeneity that requires spatially and longitudinally resolved approaches to uncover regulatory programs and guide context‐specific therapies.
Carolina Hernández‐Oliver, Neibla Priego, Manuel Valiente   +2 more
wiley   +1 more source

The person-based approach to intervention development: A scoping review of methods and applications. [PDF]

Digit Health
Holt L, Denford S, Bowers H, Kuberka P, Muller I, Amlôt R, Yardley L.   +6 more
europepmc   +1 more source